ClinicalTrials.gov
public full text
Public Domain
Sacituzumab Govitecan in Recurrent Glioblastoma
This is an open-label single arm study. All patients will receive the study drug. The aim of the study is to compare overall survival (OS) of patients with recurrent brain tumor, known as Glioblastoma (GBM) having high levels of a protein, Trophoblast cell surface antigen 2 (Trop-2), expression on treatment with Sacituzumab Govitecan (SG) versus lomustine only which has been used in the past.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of Abemaciclib in Recurrent Glioblastoma#854304
- Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma#879144
- Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)#1140651
- Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma#448257
- Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma#994305
Record · ID 880318
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive